Hemab ApS
CVR 40837590 · Private limited company (ApS) · Active · Very high risk
Hemab ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 7.8% over the next 12 months, which is 5.6 times the average for Danish companies. 6 annual reports have been published, of which 2 more than six months after the end of the financial year. CEO: Mads Nikolaj Behrndt-Eriksen.
Bankruptcy risk for Hemab ApS
5.6 × the average (1.41%) · higher risk than 96% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 40837590
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (7 years)
- Address
- Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 1.2m
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 2 of 6 |
| Missing annual report | No |
| Negative equity | – |
| Equity ratio | – |
| Current ratio | – |
| Moves (last 2 years) | 0 |
| CEO changes in total | 2 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 |
|---|
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · EY.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 181 | ||
| 1 Jan 2024 – 31 Dec 2024 | 174 | ||
| 1 Jan 2023 – 31 Dec 2023 | 178 | ||
| 1 Jan 2022 – 31 Dec 2022 | 184 | Late | |
| 1 Jan 2021 – 31 Dec 2021 | 187 | Late | |
| 27 Sep 2019 – 31 Dec 2020 | 131 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Mads Nikolaj Behrndt-Eriksen | Current | |
| CEO | Johan Henrik Faber | ||
| Board | Linda Catharina Bain | Current | |
| Board | John Michael Maraganore | Current | |
| Board | Benny Sørensen | Current | |
| Board | Akshay Krishnadas Vaishnaw | Current | |
| Board | Hans Heugh Wandall | ||
| Board | Johan Henrik Faber | ||
| Board | Kim Stengaard Holmsted | ||
| Board | Thomas Dal Stenfeldt Batchelor | ||
| Board | Hans Heugh Wandall | ||
| Board | Søren Erik Bjørn | ||
| Board | Benny Sørensen | ||
| Board | Camilla Petrycer Hansen | ||
| Board | Jørgen Søberg Petersen | ||
| Board | Thomas Dal Stenfeldt Batchelor | ||
| Board | Mårten Steen | ||
| Board | Laura Anne Tadvalkar | ||
| Board | Jørgen Søberg Petersen | ||
| Board | Daniel Becker | ||
| Board | Uya Chuluunbaatar | ||
| Board | Joseph Anderson | ||
| Owner (100%) | Hemab Therapeutics Holdings, Inc. | Current | |
| Owner (100%) | Ebumab Holding ApS | ||
| Owner (90%) | Ebumab Holding ApS | ||
| Owner (5%) | GV1 Holding ApS | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (50%) | Ebumab Holding ApS | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (25%) | Ebumab Holding ApS | ||
| Owner (5%) | RA Capital Nexus Fund II, L.P. | ||
| Owner (10%) | RA Capital Healthcare Fund, L.P. | ||
| Owner (10%) | HealthCap VIII L.P. | ||
| Owner (25%) | Novo Holdings A/S | ||
| Owner (20%) | Ebumab Holding ApS | ||
| Owner (15%) | RA Capital Healthcare Fund, L.P. | ||
| Owner (15%) | HealthCap VIII L.P. | ||
| Owner (15%) | Ebumab Holding ApS | ||
| Owner (20%) | RA Capital Healthcare Fund, L.P. | ||
| Owner (20%) | HealthCap VIII L.P. | ||
| Owner (10%) | Ebumab Holding ApS | ||
| Owner (20%) | Novo Holdings A/S | ||
| Owner (5%) | Ebumab Holding ApS | ||
| Owner (5%) | RA Capital Nexus Fund II, L.P. | ||
| Owner (10%) | RA Capital Healthcare Fund, L.P. | ||
| Owner (10%) | HealthCap VIII L.P. | ||
| Owner (15%) | AI DEN-MAB LLC | ||
| Owner (5%) | DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. | ||
| Owner (5%) | AVORO VENTURES FUND L.P. | ||
| Owner (15%) | Novo Holdings A/S | ||
| Owner (10%) | RA Capital Healthcare Fund, L.P. | ||
| Owner (5%) | HealthCap VIII L.P. | ||
| Owner (10%) | AI DEN-MAB LLC | ||
| Owner (5%) | DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. | ||
| Owner (5%) | Sofinnova Crossover II S.L.P. | ||
| Owner (5%) | SMALLCAP World Fund, Inc. | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | KAPPELSKOV REVISION. GODKENDT REVISIONSAKTIESELSKAB | ||
| Auditor | Slotsgade Revision ApS | ||
| Founder | Ebumab Holding ApS | Current |
The CEOs' other companies
Mads Nikolaj Behrndt-Eriksen – 3 other companies
- Cymab ApS Active
- Ebumab Holding ApS Active
- Mabe Invest ApS Active
Johan Henrik Faber – 4 other companies
- Cymab ApS Active
- Ebumab Holding ApS Active
- Ebumab Sandbox ApS Active
- Johan H. Faber ApS Active
Address history (1 moves)
| Nordre Fasanvej 215, 2000 Frederiksberg | |
| Ole Maaløes Vej 3, 2200 København N |
Former names
| Hemab ApS | – now |
| Ebumab Hemophilia ApS | – |
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- Muna Therapeutics ApS Frederiksberg
- LactaPure IVS Frederiksberg
- SoftOx Solutions Denmark A/S Frederiksberg
- Guldstoev Pharma IVS Frederiksberg C
- Microembed Pharmaceuticals IVS Frederiksberg
Questions and answers about Hemab ApS
Has Hemab ApS gone bankrupt?
No, Hemab ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Hemab ApS?
Our model estimates a bankruptcy risk of 7.8% over the next 12 months (very high risk), which is 5.6 times the average for Danish companies.
Who is the CEO of Hemab ApS?
Mads Nikolaj Behrndt-Eriksen is the CEO of Hemab ApS.
Who is the auditor of Hemab ApS?
Hemab ApS most recently used EY Godkendt Revisionspartnerselskab.
When was Hemab ApS founded?
Hemab ApS was founded on 27 September 2019.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.